RARE PDUFA decision: a positive outcome, +5.6%

On June 9, 2026, Ultragenyx Pharmaceutical Inc. reached its PDUFA decision. The result was a positive outcome, and the stock moved +5.6% in the window around the event. It had already run -16.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.